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EDITORIAL
Advances in structural heart disease: MitraClip for Secondary Mitral
Regurgitation — A potential game changer
Shahrukh Hashmani,1 Ammarah Yasmeen,2 Shayana Rukhsar Hashmani3
Secondary mitral regurgitation (MR) also known as the
'functional' MR, is not primarily due to underlying valve
pathology. It is due to left ventricular dysfunction either
secondary to idiopathic dilated cardiomyopathy or due to
underlying coronary artery disease (CAD). Regional or
global left ventricular (LV) systolic dysfunction and
adverse LV remodelling can cause restricted leaflet
motion and failure of leaflet coaptation resulting in MR.1
Thus, the mechanism is largely ventricular rather than
valvular. MR burdens the LV with a volume overload state
that leads to a series of compensatory myocardial and
circulatory adjustments. Eventually, the myocardium fails,
the ventricle decompensates, and the patient exhibits
signs of heart failure. It has been strongly associated with
decreased quality of life, increased rate of hospitalization
for heart failure, and shortened survival.2,3 Hence, the
prognosis among patients with heart failure and
secondary mitral regurgitation is extremely poor
associated with high mortality rates.
In the remote past, the only option to treat secondary MR
was to treat the underlying etiology. Guideline-directed
medical therapy (GDMT) and cardiac resynchronization
therapy (CRT) provided symptomatic relief, improved the
left ventricular function, and in some patients, it lessened
the severity of mitral regurgitation.4 As correction of valve
in case of primary MR improve outcomes, the contrary
was not true in case of secondary MR as the valve was
structurally normal. Hence, neither percutaneous or
surgical repair nor surgical replacement of the mitral
valve had shown to lower the rate of hospitalization or
death associated with secondary mitral regurgitation.4
Percutaneous repair by MitraClip is a transcatheter
technology based on the surgical Alfieri edge-to-edge
repair, which involves suturing together the middle
segments of the anterior and posterior mitral valve
leaflets, thereby creating a "double orifice" mitral
regurgitant area.5 The MitraClip system utilizes a cobalt
chromium clip covered with a polypropylene fabric that
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grasps the leaflet and reduces mitral regurgitation (MR)
by increasing the coaptation between the regurgitant
valve leaflets. In some cases, a second clip may be
required to adequately reduce the MR severity toward a
goal of final regurgitant severity <2+.6
In The Endovascular Valve Edge-to-Edge Repair Study
(EVEREST) II trial, transcatheter mitral-leaflet
approximation with the MitraClip device was found to be
safer than surgical mitral-valve repair but was not as
effective in reducing the severity of mitral regurgitation.7
In August, 2018; Mitra FR trial was published that showed
that in patients with secondary MR, the rate of death or
unplanned hospitalization for heart failure at 1 year did
not differ significantly between patients who underwent
percutaneous mitral-valve repair in addition to receiving
medical therapy and those who received medical therapy
alone.8 But the recently published landmark trial "COAPT
- Cardiovascular Outcomes Assessment of the MitraClip
Percutaneous Therapy for Heart Failure Patients with
Functional Mitral Regurgitation trial contradicted the
Mitra FR trial. These investigators showed that in patients
with moderate to severe or severe secondary mitral
regurgitation that remained symptomatic despite the use
of maximal tolerated doses of GDMT, transcatheter mitralvalve repair resulted in a lower rate of hospitalization for
heart failure and lower all-cause mortality within 24
months of follow-up than medical therapy alone.9
COAPT trial is a randomized controlled trial that had two
groups; one group was assigned to GDMT while the other
group had mitra clip in place in addition to the GDMT.
With long follow up of 2 years, the rate of hospitalization
for heart failure significantly reduced in the group
receiving mitra clip. Similarly, all-cause mortality was also
significantly decreased in the device group. (Figure A and
B) The rate of freedom from device related complications
at 12 months was significantly lower as compared to both
the EVEREST-II trial and MITRA FR trial. One of the reasons
why this trial was successful was that the procedural
success rates for MitraClip implantation was 98%, with
immediate achievement of a MR grade of 2+ or lower
(moderate MR or less) in 95% of the patients. This was also
durable over time with only 0.9% of patients reporting
3+MR (severe MR) at 2 years follow up compared to 14%
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Figure: A shows rates of hospitalization for heart failure were significantly reduced at 24 months in the device group compared to the control group Similarly Panel. B, shows decrease
mortality in device group compared to the control group.

as reported in previous trials.10 The results from COAPT
trial can have a significant impact on the management of
patients with secondary MR.
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In conclusion, COAPT trial showed that in patients with
moderate-to-severe or severe secondary mitral
regurgitation with heart failure who remained
symptomatic despite the use of maximal doses of GDMT,
transcatheter mitral valve repair (MitraClip) resulted in a
lower rate of hospitalization for heart failure, lower
mortality, and better quality of life and functional capacity
within 24 months of follow-up than medical therapy
alone.
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